FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound), FDA Approved for Treatment of Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor, Available at Biologics by McKesson
CARY, N.C., Dec. 22, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Aadi Bioscience as a specialty pharmacy provider for FYARROTM (sirolimus protein-bound particles for injectable suspension) (albumin-bound). FYARRO was approved by the U.S. Food and Drug Administration (FDA) on November 22,2021. This therapy is a […]